Tarlige Dosage/Direction for Use

Posology: For adults, administer mirogabalin at an initial oral dose of 5 mg twice daily, and then increase the dose by 5 mg per dosing with an interval of at least 1 week up to 15 mg twice daily. The dose may be increased or decreased appropriately in the range between 10 mg and 15 mg twice daily, based on individual patient age or symptoms.
Renal Impairment: Since mirogabalin concentrations in plasma may increase in patients with reduced renal function, possibly increasing the risk of adverse reactions, careful administration with close monitoring is necessary for these patients. For patients with renal impairment, the dose and dosing intervals should be adjusted, referring to creatinine clearance levels listed in Table 8. Treatment should be started at a low dose, and the dose should be increased in patients who show confirmed tolerability but insufficient effect (see Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions). (See Table 8.)

Click on icon to see table/diagram/image

Pediatric population: Clinical studies in children have not been conducted.
Elderly population: TARLIGE should be administered with care, and dose and dosing interval adjustment based on creatinine clearance levels is required. Elderly patients often have reduced renal function (see Pharmacology: Pharmacokinetics under Actions).
Elderly patients tend to experience falls resulting in fractures, etc. led by events (e.g., dizziness, somnolence, loss of consciousness) (see Precautions).
Hepatic Impairment: No dose adjustment is required for patients with hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).
Method of administration: For oral use.
TARLIGE can be taken with or without food (see Pharmacology: Pharmacokinetics under Actions).